Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors

2023-509688-25-00 Protocol PM14-A-003-20 Human pharmacology (Phase I) - Other Ended

Start 23 Nov 2021 · End 19 Sep 2025 · Status Ended · 1 EU/EEA countries · 5 sites · Protocol PM14-A-003-20

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 50
Countries 1
Sites 5

Advanced solid tumors

Key facts

Sponsor
Pharma Mar S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
23 Nov 2021 → 19 Sep 2025
Decision date (initial)
2024-07-23
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-509688-25-00
EudraCT number
2021-000833-15

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced solid tumors

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pharma Mar S.A.

Sponsor organisation
Pharma Mar S.A.
Address
Avenida De Los Reyes 1, Poligono Industrial La Mina Poligono Industrial La Mina
City
Colmenar Viejo
Postcode
28770
Country
Spain

Scientific contact point

Organisation
Pharma Mar S.A.
Contact name
Clinical Development Oncology Unit

Public contact point

Organisation
Pharma Mar S.A.
Contact name
Clinical Development Oncology Unit

Locations

1 EU/EEA country · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 50 5
Rest of world 0

Investigational sites

Spain

5 sites · Ended
Hospital Universitario Hm Sanchinarro
START Madrid-HM CIOCC, Calle Ona 10, 28050, Madrid
University Hospital Virgen Del Rocio S.L.
Oncology, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital General Universitario Gregorio Maranon
Oncology, Calle Del Doctor Esquerdo 46, 28009, Madrid
Institut Catala D'oncologia
Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital Universitari Vall D Hebron
Medical Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2021-11-23 2021-12-10 2025-08-19

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-03 Spain Acceptable with conditions
2024-07-23
2024-07-23
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-13 Spain Acceptable
2025-02-04
2025-02-18
3 SUBSTANTIAL MODIFICATION SM-2 2025-03-04 Spain Acceptable 2025-03-17